In this edition of CEOinsiderTV we’ll speak with Mr. Michael Rhodes CEO of Allerayde SAB Inc. (ASAB, OTC:ASAB, ASAB.PK)
Allerayde is a public company trading on the over the counter market under the ticker symbol ASAB
In this video interview you’ll discover:
- How Allerayde combined two seemingly impossible goals in building a third-generation anaphylaxis, auto-injector pen
- The secret weapon ASAB will deploy to achieve broad distribution and quickly build international market share.
- The Allerayde innovation that will meld “iphone-like” features into their new emergency allergy treatment product
- Why Allerayde’s third-generation AAApen has a unique edge over competing products in non-traditional markets and why this could make ASAB’s revenues soar beyond expectations
- How acquisitions play into ASAB’s future growth plans…
- And much more.
Watch this entire video interview to learn more about Allerayde SAB, Inc. and their groundbreaking, cost effective and highly profitable approach to treating life-threatening allergic reactions.